Black Diamond Therapeutics (BDTX) Interest Expenses (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Interest Expenses came in at $1.1 million in Q1 2026, up 2.71% YoY from $1.1 million in Q1 2025, and little changed on a QoQ basis from $1.1 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Interest Expenses (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Interest Expenses data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Interest Expenses rose 2.71% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 2.7% YoY) and the FY2025 annual result came in at $124.2 million, down 2.64% from the prior year.
- Interest Expenses steadied at $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $35.7 million in Q3 2022 to a low of $584000.0 in Q2 2025.
- A 5-year average of $8.1 million and a median of $1.1 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 324.23% — and 2025, when it sank 97.93%.
- Tracing BDTX's Interest Expenses over 5 years: stood at $1.1 million in 2022, then grew by 2.76% to $1.1 million in 2023, then rose by 2.69% to $1.1 million in 2024, then rose by 2.71% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
- The last three Interest Expenses figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122,000.00 |
| Jun 30, 2026 | 122,000.00 |
| Mar 31, 2026 | 1.14 Mn |
| Mar 31, 2026 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Jun 30, 2025 | 584,000.00 |
| Jun 30, 2025 | 584,000.00 |
| Mar 31, 2025 | 1.11 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 7.36 Mn |
| Sep 30, 2024 | 7.36 Mn |
| Jun 30, 2024 | 28.25 Mn |
| Jun 30, 2024 | 28.25 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.08 Mn |